Year Founded
2018
Ownership
Private
Employees
~50
Therapeutic Areas
Oncology
Stage
Phase 2
Modalities
Bispecific antibodySmall molecule

Curon Biopharmaceutical General Information

Lead asset CN201 (CD19xCD3 bispecific antibody) in Phase 1/2 for B-ALL. Second program CN401 targeting PI3K gamma/delta in Phase 1/2 for lymphomas.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Shanghai, Shanghai
China

Drug Pipeline

CN201
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Curon Biopharmaceutical's pipeline data

Book a demo

Key Partnerships

Merck

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Curon Biopharmaceutical Funding

Deal TypeDateAmountStatusStage
Later Stage VCJul 30, 2018$150.0MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Curon Biopharmaceutical's complete valuation and funding history, request access »

Curon Biopharmaceutical Investors

Temasek Holdings Ltd.
Investor Type: Venture Capital
Holding: Minority
Boyu Capital Group Ltd.
Investor Type: Venture Capital
Holding: Minority
6 Dimensions Capital
Investor Type: Venture Capital
Holding: Minority